ROLE OF ALLOANTIGENS IN NATURAL KILLING
Allogeneic but Not Autologous Tumor
Biopsy Cells Are Sensitive for Interferon-induced
Cytotoxicity of Human Blood Lymphocytes*

By FARKAS T. VÁNKY, SHMUEL A. ARGOV, STEFAN A. EINHORN, AND EVA KLEIN

From the Department of Tumor Biology, Karolinska Institute; and the Radiumhemmet, Karolinska
Hospital, S-104 01 Stockholm 60, Sweden

Interferon (IF)\(^1\) is known for its effect on virus cell interactions (1). The first
indication that it could influence cellular cytotoxicity was provided by Svet-Moldav-
sky and Chernyakovskaya in 1967 (2), when they observed that lymphocyte-mediated
killing was enhanced in the presence of IF. Their system comprised mouse lymphocytes
and the L cell line. This finding was not followed up until 1972 when Lindahl et al.
(3) reported that IF enhanced the specific cytotoxicity of allosensitized murine T cells.
Recent experiments established that exposure of lymphocytes to IF in vitro elevates
their natural killer (NK) activity (4-6). In addition, treatment of the lymphocyte
donors with IF or IF inducers also leads to increased in vitro cytotoxic potential (7-9).
The cytotoxic system is influenced in the opposite direction if the targets are treated
with IF inasmuch as their susceptibility for killing is decreased (10).

IF is used in tumor therapy because of its antitumor (11), antiviral, and immuno-
potentiating effects. Beneficial effects have been reported for Hodgkin's lymphoma
(12), myelomatosis (13), malignant lymphoma, (14) and leukemia (15).

In the majority of studies dealing with NK and the IF-activated killing (IAK),
established cell lines were used as targets. In experimental systems, freshly harvested
cells usually had lower NK sensitivity than cultured lines (16, 17). Also, in man,
tumor cells isolated from biopsies were generally NK resistant, i.e., they were not
killed by allogeneic lymphocytes derived from healthy donors (18). On the other
hand, a tumor-specific reactivity was indicated in 28% of 156 cases because the biopsy
cells were damaged by the autologous lymphocytes (19). We refer to this effect as
autologous lymphocyte-mediated cytotoxicity (ALC).

The experiments reported in this paper were initiated with the aim to investigate
whether IF treatment in vitro influences the ALC. Such effects would have provided
an in vitro correlate for the therapeutical effect of IF. The results were negative
inasmuch as no ALC was induced. The ALC-negative cases remained negative, and
no elevation of the existing effects occurred.

* Supported in part by federal funds from the Department of Health, Education, and Welfare under
contract NOI-CB-74144, by the Swedish Cancer Society, and by the Stanley Thomas Johnson Foundation,
Bern, Switzerland.

\(^1\) Abbreviations used in this paper: ALC, autologous lymphocyte-mediated cytotoxicity; ATS, autologous
tumor stimulation; Con A, concanavalin A; FI, Ficoll-Isoaque; IAK, interferon-activated killing; IF,
interferon; MHC, major histocompatibility complex; NHS, normal human sera(um); NK, natural killer.

J. Exp. Med. © The Rockefeller University Press • 0022-1007/80/05/1151/15 $1.00 1151
Volume 151 May 1980 1151-1165
An interesting phenomenon, however, was discovered in that IF-induced cytotoxicity was efficient only in allogeneic combinations. Because the IAK has been shown to be performed by those lymphocyte subsets that are also responsible for the NK (20, 21), this finding may contribute to the understanding of the NK mechanism. It is likely that IF activates the cytotoxic potential of the lymphocyte population, and that those cells that carry the receptors for the histocompatibility antigens expressed on the particular target can manifest the cytotoxic function.

**Materials and Methods**

**Patients.** 43 patients with solid tumors of various histologic types were studied (Table I). Except for eight patients (1019, 1020, 1023, 1024, 1027, 1032, 1034, and 1035) who had osteosarcomas and were receiving IF (3 million U/d) and seven patients (1127, 1120, 1113, 0788, 0508, 0509, 0510) who were operated earlier for their primary tumors, the patients were not treated before the tumor and blood sampling.

**Tumor Cells.** These cells were separated from biopsy specimens according to our procedure described elsewhere (22), by the stepwise application of velocity and density sedimentations on Ficoll-Isoopaque (FI) (Pharmacia Fine Chemicals, Inc., Upsala, Sweden) and/or human serum albumin gradients, treatment with collagenase and DNase, and adherence to plastic surface. The isolated tumor cells were incubated overnight in culture conditions before the cytotoxic test to allow regeneration of putative antigens assumed to be affected during the procedures of cell separation. Experiments were performed only with cell suspensions that had at least 80% cell viability, as assessed by trypan blue exclusion, and had <5% obvious contamination with nonmalignant cells.

**Storage of Tumor Cells.** Samples of tumor cells (2-5 \( \times 10^6 \)) were stored in liquid nitrogen for use as targets in repeated tests. The cells were suspended in 0.5 ml of RPMI-1640 medium (Flow Laboratories, Ltd., Irvine, Ayrshire, Scotland) that contained 40% normal human serum (NHS), after which 0.5 ml of 20% dimethyl sulfoxide in RPMI-1640 medium was added dropwise. Ampules were frozen at 1°C/min. After thawing, cells were diluted to 10 ml with RPMI-1640 medium plus 20% NHS, centrifuged, and resuspended in RPMI-1640 medium plus 10% NHS. When necessary, dead cells were removed by centrifugation on FI gradients.

**Cell Lines.** The erythroid line K-562 was derived from a patient with chronic myeloid leukemia in blast crisis (23). The T cell line Molt-4 was obtained from a patient with acute lymphoid leukemia (24). They were maintained in suspension culture in RPMI-1640 medium supplemented with 10% fetal calf serum.

**Lymphocytes.** Lymphocytes from 43 patients and 49 healthy donors were separated from heparinized blood on FI, followed by incubation in Falcon plastic culture flasks (type 3024, Falcon Labware, Div. of Becton, Dickinson & Co., Oxnard, Calif.) for 30 min at 37°C and by passage through a nylon fiber column (25). The nylon fiber column-passed populations contained 91 ± 6% sheep erythrocyte-rosetting cells. Contamination with cells of obviously nonlymphocyte morphology represented <1%.

**IF Preparations.** The partially purified Sendai virus-induced human leukocyte IF preparations were received from Dr. Kari Cantell, Central Public Health Laboratory, Helsinki, Finland. They were produced and purified as previously described (26). The antiviral activities of the preparations were determined by assaying inhibition of plaques induced by vesicular stomatitis virus in human amnion (U) cells (27) and expressed in international reference units by comparison with the international reference preparation 69/19. The antiviral activities of the preparations were ~6 \( \times 10^6 \) U/ml, with an ~10^6 U/mg of protein sp act.

**IF Treatment of the Lymphocytes.** Aliquots of lymphocytes (3-10 \( \times 10^6 \)) were incubated with or without 1,000 U/ml IF for 1-3 h at 37°C in culture medium. The cells were then washed and used as effectors in the cytotoxicity tests. IF treatment of the lymphocytes had no effect on cell viability as assessed after crystal violet staining. The cytotoxicity of these lymphocytes will be referred to as IAK.

**Medium.** RPMI-1640 medium with l-glutamine (200 mM solution, 1% by vol), benzylpenicillin (100 IU/ml), streptomycin sulfate (100 μg/ml), Hepes buffer (0.1 mM/ml), and heat-
TABLE I
List of Patients

| Patient number | Sex | Age | Diagnosis | Clinical stage | Differentiation* |
|----------------|-----|-----|-----------|----------------|-----------------|
|                |     |     |           |                |                 |
| 1019           | M   | 20  | Osteosarcoma | Localized      | L               |
| 1020           | M   | 20  | Osteosarcoma | Localized      | L               |
| 1023           | M   | 15  | Osteosarcoma | Lung metastasis| L               |
| 1024           | F   | 14  | Osteosarcoma | Localized      | L               |
| 1027           | M   | 25  | Osteosarcoma | Localized      | L               |
| 1028           | M   | 15  | Osteosarcoma | Localized      | L               |
| 1034           | M   | 17  | Osteosarcoma | Localized      | L               |
| 1035           | M   | 11  | Osteosarcoma | Lung metastasis| L               |
| 1025           | M   | 51  | Malignant chordoma | Local recurrence | D               |
| 1028           | M   | 74  | Malignant mesenchymal tumor | Lung metastasis | U               |
| 1031           | M   | 70  | Malignant mesenchymal tumor | Localized | U               |
| 1115           | F   | 77  | Malignant mesenchymal tumor | Localized | U               |
| 1131           | M   | 75  | Malignant histiocytic tumor | Lymph node metastasis | L               |
| 1033           | M   | 43  | Fibrosarcoma of the tibia | Localized | L               |
| 1126           | M   | 59  | Fibrosarcoma | Localized      | L               |
| 1130           | F   | 71  | Myxoid fibrosarcoma | Localized | L               |
| 1127           | M   | 77  | Liposarcoma | Local recurrence | L               |
| 0111           | M   | 43  | Liposarcoma | Localized      | L               |
| 1120           | M   | 52  | Myxoid liposarcoma | Local recurrence | D               |
| 1121           | F   | 60  | Myxoid liposarcoma | Localized | D               |
| 1117           | F   | 76  | Synovial sarcoma | Localized | L               |
| 1113           | F   | 60  | Melanoma | Lung metastasis | D               |
| 0788           | F   | 46  | Melanoma | Brain metastasis | D               |
| 2256           | F   | 52  | Thymoma | Localized      | D               |
| 2258           | M   | 59  | Thymoma | Localized      | D               |
| 2259           | F   | 58  | Thymoma | Localized      | D               |
| 0500           | M   | 55  | Hypernephroma | Localized | D               |
| 0508           | M   | 54  | Hypernephroma | Lung metastasis | L               |
| 0509           | M   | 66  | Hypernephroma | Lung metastasis | L               |
| 0510           | F   | 70  | Hypernephroma | Brain metastasis | L               |
| 2217           | M   | 69  | Adenocarcinoma of the lung | Lymph node metastasis | D               |
| 2224           | M   | 62  | Adenocarcinoma of the lung | Localized | L               |
| 2229           | F   | 51  | Adenocarcinoma of the lung | Localized | D               |
| 0470           | M   | 80  | Adenocarcinoma of the lung | Localized | D               |
| 2225           | M   | 63  | Squamous cell carcinoma of the lung | Localized | L               |
| 2234           | F   | 59  | Squamous cell carcinoma of the lung | Localized | D               |
| 2244           | M   | 51  | Squamous cell carcinoma of the lung | Localized | L               |
| 2255           | M   | 30  | Squamous cell carcinoma of the lung | Localized | L               |
| 0012           | M   | 72  | Squamous cell carcinoma of the lung | Inoperable | L               |
| 0013           | M   | 61  | Squamous cell carcinoma of the lung | Inoperable | D               |
| 2219           | M   | 67  | Oat cell carcinoma of the lung | Lymph node metastasis | U               |
| 0784           | F   | 51  | Astrocytoma grade III | | |
| 0787           | F   | 25  | Astrocytoma grade II | | |

* L, low differentiation; U, undifferentiated; D, differentiated.

inactivated serum (from healthy male donors) added in 10% concentration was used in all experiments. NHS were not preselected, but cloudy sera were excluded.

Cytotoxicity Assay. A modification of the method described by Vose et al. (28) has been used. Target cells (10⁶) were labeled in 0.5 ml medium by the addition of 100 µCi ⁵¹Cr (as sodium
Effect of IF on the Cytotoxicity of Lymphocytes Against Autologous and Allogeneic Tumor Biopsy Cells and Against K-562

| Number | Diagnosis               | Incubated with IF* | Tumor biopsy cell number | K-562 |
|--------|-------------------------|--------------------|--------------------------|------|
| 1115   | Malignant mesenchymal tumor | 8 (27)§           | 5 (37)                   | 22 (25) |
|        |                         | 6                  | 44§                      | 31    |
| 0111   | Liposarcoma              | 22                 | 76¶                      | 41§    |
|        |                         | 11                 | 4                        | 25     |
|        |                         | 33§                | 22¶                      | 30§    |

* The lymphocytes were incubated with 1,000 U/ml IF for 1 h and washed before the test.
§ P < 0.01 between the values obtained with lymphocytes with and without IF treatment.
¶ P < 0.001 between the values obtained with lymphocytes with and without IF treatment.
¶ P < 0.05 between the values obtained with lymphocytes with and without IF treatment.

Results

Effect of IF on Lymphocyte Cytotoxicity Against Primary Tumor Biopsy Cells. Table II presents the results of an experiment in which two patients (malignant mesenchymal tumor 1115 and liposarcoma 0111) and one healthy donor were involved. After pretreatment of the lymphocytes with IF, the NK activities were measured as the...
TABLE III

Effect of IF on the Cytotoxicity of Lymphocytes Against Autologous and Allogeneic Tumor Biopsy Cells and Against Molt-4

| Donor   | Diagnosis       | Targets |
|---------|-----------------|---------|
|         | Incubated with IF* | Tumor biopsy cell number | Molt-4 |
|         |                  | 0509    | 0508    |        |
| 0509    | Hypernephroma - | 50 (42)§ | 10 (38) | 14 (24) |
| 0509    | Hypernephroma + | 45      | 26§      | 21      |
| 0508    | Hypernephroma - | 2       | 0        | 32      |
| 0508    | Hypernephroma + | 47|| | 5        | 49§      |
| Healthy | -                | 43      | 24       | 89      |
| Healthy | +                | 62|| | 83§      | 83      |

* The lymphocytes were incubated with 1,000 U/ml IF for 1 h and washed before the test.
† The values represent the percent specific 51Cr release and those in parentheses indicate the percent spontaneous 51Cr release.
§ P < 0.05 between the values obtained with lymphocytes with and without IF treatment.
||P < 0.001 between the values obtained with lymphocytes with and without IF treatment.

Elevated anti-K-562 effect. Except for the effect of the 0111 lymphocytes on the 1115 targets, the effects against primary biopsy cells were weaker than against K-562. IF treatment regularly enhanced the killing of allogeneic targets. This was not the case for ALC.

The results of an experiment with lymphocytes from two hypernephroma patients and one healthy blood donor are given in Table III. The NK activity of the patients, as measured against Molt-4, was weaker than that of the control donor. The strong NK activity of the lymphocytes of the healthy donor is also reflected by the cytotoxicity against the biopsies. The lymphocytes of patient 0509 killed the autologous tumor cells. This activity was not elevated by IF pretreatment, whereas allo-killing was induced. The lymphocytes of patient 0508 were inactive against both the autologous and the allogeneic tumor cells. IF treatment of the lymphocytes induced strong cytotoxicity against the allogeneic biopsy cells.

Table IV shows a test with lymphocytes and tumor cells from a synovial sarcoma (1117) and an osteosarcoma (1020) patient. The standard NK activity (anti-K-562) of the lymphocytes of the patients was augmented by IF. Cytotoxicity against the biopsy cells was increased by IF only in the allogeneic combinations.

The summary of ALC experiments with lymphocytes from 25 tumor patients is presented in Fig. 1a and Table V. ALC occurred in 7 (28%) cases. In an additional four cases, the specific 51Cr release was between 10 and 20%. In 24 of 25 cases, incubation of the lymphocytes with IF did not significantly change the level of ALC, whereas in one it decreased the killing potential (of the 24 cases in which the change was not significant, the 51Cr-release values were higher in 10 and lower in 10 cases).

The results of cytotoxicity against allogeneic biopsy targets with lymphocytes from 46 healthy donors and 24 tumor patients are presented in Fig. 1b and c, respectively. The controls were active in 7 of 50 (14%) tests (Fig. 1b), and, in 5 of these 7, IF increased the cytotoxic efficiency. Of the 43 negative tests, IF treatment caused significant cytotoxicity in 22. The specific 51Cr release was somewhat enhanced in an additional 10 cases, diminished in 7, and equal to that of untreated samples in 6. The
### Table IV

**Effect of IF on the Cytotoxicity of Lymphocytes Against Autologous and Allogeneic Tumor Biopsy Cells and Against K-562**

| Lymphocytes Donor Incubated with IF* | Targets Tumor biopsy cell number | K-562 |
|-------------------------------------|---------------------------------|-------|
| Number | Diagnosis | 1117 | 1020 |
| 1117 | Synovial sarcoma - | 17 (40)‡ | 4 (44) | 36 (28) |
| 1117 | Synovial sarcoma + | 20 | 14 | 57§ |
| 1020 | Osteosarcoma - | 9 | 20 | 4 |
| 1020 | Osteosarcoma + | 31‖ | 22 | 26§ |
| Healthy - | 7 | 0 | 28 |
| Healthy + | 30‖ | 39‖ | 32 |

* The lymphocytes were incubated with 1,000 U/ml IF for 3 h and washed before the test.
‡ The values represent the percent specific 
§ P < 0.01 between the values obtained with lymphocytes with and without IF treatment.
‖ P < 0.001 between the values obtained with lymphocytes with and without IF treatment.

---

Fig. 1. Influence of IF on the cytotoxic potential of lymphocytes exerted on primary tumor cells (a) in autologous combination, (b) by lymphocytes of healthy donors, and (c) by lymphocytes of tumor patients towards allogeneic target cells.

increase (± SE) in the mean percent specific ⁵¹Cr release with IF-treated lymphocytes from healthy donors was 12 ± 2.6, and this was statistically significant (P < 0.001).

The results with the tumor patients were similar. They showed a significantly lower proportion of allogeneic cytotoxicity, i.e., in 2 of 37 (5%) of the tests (Fig. 1c). In 18 of 37 tests, IF-treated lymphocytes exhibited significant cytotoxicity. The specific ⁵¹Cr release was elevated in an additional eight cases, diminished in eight, and equal to
TABLE V

**IF-induced Cytotoxicity of Blood Lymphocytes Against Tumor Biopsy Cells**

| Targets (tumor biopsy cells) | Effector lymphocyte from | Tumor patient | Healthy donor |
|-----------------------------|--------------------------|---------------|---------------|
|                             | IF−  | IF+  | Change in IF+ percent | IF−  | IF+  | Change in IF+ percent |
|                             | release |  | 51Cr release | release |  | 51Cr release |
| Autologous                  | 7/25 (28%)* | 7/25 (28%) | −0.3 ± 1.6‡ | — | — | — |
| Allogeneic                  | 2/37 (5%) | 18/37 (49%) | 12.7 ± 2.6 | 7/50 (14%) | 26/50 (52%) | 14.9 ± 2.2 |

* Cases with statistically significant cytotoxicity per number of tests.
‡ Mean percent increase of the specific 51Cr release ± SE, as a result of IF treatment of the effectors.

Fig. 2. Influence of IF on the (▲) anti-K-562 and (●) anti-Molt-4 activity of lymphocytes of tumor patients.

that of untreated lymphocytes in three. The difference in the mean percentage specific 51Cr release (± SE) between the IAK and NK was 14.9 ± 2.2, and this was also statistically significant (P < 0.001).

A summary of the IAK results is given in Table V. ALC was similar with IF-treated and untreated lymphocytes. The mean percentage of difference was −0.3 ± 1.6. The
lower NK efficiency of the lymphocytes of the tumor patients is reflected by the lower frequency of allo-killing (5%) compared with the 14% obtained with effectors from healthy donors. There was no significant difference between the proportion of IAK-positive tests of the patients and controls with allogeneic biopsy targets (49 and 52%, respectively).

Eight osteosarcoma patients received IF therapy at the time of tumor and blood sampling. The results with this group of patients did not differ from the general pattern either in the efficiency of the effectors or the sensitivity of the targets.

Lymphocytes from 12 patients were assayed against the K-562 and/or Molt-4 lines. In all 26 tests (Fig. 2) the IAK was elevated over the NK. Repeated tests gave similar results. In accordance with previous findings, the NK efficiency of lymphocytes from healthy donors was stronger than that of the tumor patients. The mean $^{51}$Cr-release values in healthy donors and tumor patients was 44.8 and 14.5% for K-562, and for Molt-4 63.4 and 27.6%, respectively.

Alteration of the Cytotoxic Susceptibility of Biopsy Cells after Cultivation. In three experiments, the tumor cells were used as targets directly, after 5–6 d of cultivation, or after preservation in frozen state. The effector cells were used with and without pretreatment with IF (Table VI). In accordance with the above described results, IF did not affect the reactivity against fresh or frozen stored autologous cells. Lymphocytes of three healthy individuals and of one tumor patient (1131) showed no NK against fresh or frozen stored allogeneic targets, whereas IAK was efficient in two of four
F. T. VÁNKY, S. A. ARGOV, S. A. EINHORN, AND E. KLEIN

After 6 d in culture, the cytotoxic sensitivity of the biopsy cells increased, and, in two of three tests, the ALC was positive (2259 and 0788). All three tests were positive after IF treatment of the lymphocytes.

In two of four cases, the cultured targets were NK sensitive, and in all four tests IAK sensitive.

Discussion

The lack of induction of ALC by in vitro IF treatment of the lymphocytes does not exclude the fact that in the complexity of the prevailing events, in vivo administration of IF can enhance the antitumor activity of the immune system. The immune response comprises interactions between several components, humoral and cellular, and the outcome might be influenced by IF acting on other levels than the direct cytotoxic effect of lymphocytes.

In previous experiments, ALC, i.e., cytotoxicity of the patients lymphocytes against their own tumor cells, was obtained in 27% of 198 cases. The effects were usually weak. The reactivity was exerted by the T cell-enriched subset and mainly autologous tumor cells were affected (29, 18). Although not proven, we may consider the in vitro cytotoxicity as a manifestation of antitumor autoimmunity. Induction of DNA synthesis in lymphocytes by the autologous tumor biopsy cells (autologous tumor stimulation [ATS]) is an additional parameter that suggests the occurrence of a tumor-specific cellular reaction (30, 31). ATS was demonstrated in higher proportion of cases (68%) than ALC (32). The reason why ALC was not influenced by IF treatment of the lymphocytes is unclear. It may be a result of the low number of antigen-recognizing lymphocytes and/or the weak expression of the relevant antigens on the targets.

In studies concerned with the characteristics of the NK, freshly harvested targets were usually resistant or were weakly sensitive in short-term cytotoxicity tests (16). In accordance, human tumor biopsy cells were rarely killed by allogeneic lymphocytes (18, 19). As shown in our results, when killing occurred, the effectors were exceptionally active against the standard NK targets.

In one study, designed to clarify the conditions that influence the NK susceptibility of the target, it was shown that the sensitivity of the same mouse tumor line changed depending upon whether it was derived from cultures or from animals (17). Our results with the human biopsy cells show a similar phenomenon. The reactivities that appear after in vitro cultivation may be the consequence to a quantitative or qualitative change in the expression of surface antigens. Such changes after explantation have in fact been demonstrated in a murine lymphoma system both for the histocompatibility (decrease) and virus-determined antigens (increase) (33). The TL antigen expressed on certain murine leukemias was also found to be modulated, it was detectable on cells kept in vitro although absent from cells harvested from immunized animals (34). Another alternative may be that in the conditions prevailing in culture those cell membrane properties that determine the sensitivity for cytotoxicity are changed. An increase in the sensitivity toward complement-mediated immune killing was observed after treatment of the targets with antimetabolites, perhaps because of an effect on cell membrane repair mechanisms (35).

We may also consider the possibility that IF is responsible for the relatively low sensitivity of primary cells (10). Immune IF may be produced in the patients in the
course of an anti-tumor response, and this may cause the relatively low NK sensitivity of the tumor cells. These alternatives are speculative, and it remains to be seen what the factor is that is responsible for the changed susceptibility toward lymphocyte-mediated killing after explantation.

The experiments revealed an interesting aspect concerning the involvement of the histocompatibility antigens in the natural killing. In the majority of NK studies, cultured lines and most often tumor lines were used as targets. The recognition seems not to be specific because sensitive cells are killed without discrimination. Tests performed with lymphocytes, of various individuals often differ in efficiency, but the ranking order of damage exerted on the various targets is similar (36, 37).

NK phenomenon is operationally defined as the cytotoxicity exerted by lymphocytes harvested from individuals without known sensitization history toward the target. IF treatment is known to enhance this effect, and the effector cells of NK and IAK were shown to be in the same subsets (20). IAK performed with the lymphocytes of donors without known immunization toward the target may be regarded as an enhanced NK phenomenon and also affects such targets that have low NK sensitivity. We may consider the situation as follows: The individual lymphocytes in the population function at various levels of intensity. For the different targets, the threshold of the intensity necessary to bring about damage seems to differ, hence the differences in the proportion of target killed by a given number of effector cells. It is unknown whether the critical factor acts at the event of establishment of the contact or at the event of the lethal hit. The results of cold target inhibition experiments would suggest the former because the competitive capacity of a particular target usually parallels its cytotoxic sensitivity. Two sets of experiments provided evidence that the elevated IAK, as compared with NK, in a given system is a result of recruitment of new cells that can kill the target, rather than action on the already active cells in such a way that each kill an increased number of targets. These experiments were (a) comparative limiting dilutions of effectors in NK and IAK using the same target, which showed an increased number of active samples in IAK; and (b) elimination of NK cells by preexposure of the lymphocytes to fibroblast monolayer that left potentially active cells inducible by IF treatment (38). In addition, results with an in vivo system also pointed to this mechanism. When rats were depleted of NK activity by radiation or drug treatment and injected with IF inducers, NK cells were found to reappear within a short time (39).

A likely explanation for the allogeneic killing induced by IF in our experiments is a polyclonal activation of the cytotoxic potential that is then manifested by the lymphocytes committed to the alloantigen specificities expressed on the particular target cells. The role of the specific receptors may be the establishment of contact between the interacting cells. Experiments concerned with the nature of NK and IAK have not yet revealed the recognition of alloantigens, although it may be the cause of a certain degree of specificity and is often detectable superimposed on cross-reactivities. Some indications for the recognition of alloantigens were seen when in vivo activated murine killer cells were tested on macrophage targets in a 16-h assay. The effect was weaker on syngeneic compared with allogeneic targets (40). However, in other series

Masucci, M. G., G. Masucci, E. Klein, and W. Berthold. Interferon induced cytotoxicity of human lymphocytes. Manuscript submitted for publication.
of experiments efficient killing of syngeneic primary target of nontumor origin such
as thymus cells was reported (41). These latter effects may, however, also represent a
killing as a result of the recognition of cell surface antigens. Mice are known to harbor
endogenous viruses that impose surface antigens on certain cell types, and these are
known to be recognized by the immune system (42). It seems that the conditions to
reveal the alloantigen-determined killing have to be strict in the sense that cultured
target cells have to be avoided.

The activation of cytotoxic precursors by IF and the manifestation of cytotoxicity
toward cells that carry alien histocompatibility antigens is similar to the findings with
mitogen-activated murine cells. The murine system has the advantage that the
influence of the major histocompatibility antigens can be easily studied in detail with
co-isogeneic strains. The phenomenon described by several authors (43-45) is as
follows: Spleen cells were activated in vitro with Concanavalin A (Con A), and this
killing effect was tested after the lectin was removed by incubation with α-methyl-D-
mannoside. Cytotoxicity was exerted by the activated lymphocytes only toward
targets that expressed alien major histocompatibility complex (MHC) locus-deter-
dined antigens. Differences in the loci of minor histocompatibility antigens and
expression of tumor-related antigens were not sufficient to bring about this reaction.
This type of cytotoxicity differed from that obtained in the presence of lectin, which
was indiscriminative and also affected histocompatible cells. The interpretation
proposed was that Con A activates precursors for expression of cytotoxic potential
and in a particular test the clone that was committed to the MHC antigens present
on the target exerted the killing. Because it is known that the frequency of lymphocytes
that recognize MHC antigens is high, such cytotoxicities are often measurable without
the necessity of the enlargement of the reactive clone. This mechanism may also be
applicable to the NK and IAK systems due to the restriction to allogeneic targets.

The search for a particular antigen responsible for the NK effect did not give
support for the existence of a well-defined entity. It is possible that membrane
properties of cultured cell lines contribute to the interaction with the killer cells.
Similar to the cytotoxicity in the presence of lectins, such interactions have a certain
specificity inasmuch as targets from the same species are affected with considerably
higher efficiency than xenogeneic targets that are sensitive to the NK exerted by the
lymphocytes of their own species (36, 46). It is known that the number of lymphocytes
that recognize cell surface antigens of an alien species is relatively low. A species-
specific recognition on the cell membrane level has also been indicated when T cells
and thymocytes were admixed to various target cells. They attached to cells in a
species-specific pattern, distinguishing their own and closely related species (47).

The cell membrane property acquired in culture conditions that contribute to the
suicidal interaction with the lymphocytes is unknown. With freshly harvested cells
this factor is absent, and the effect exhibited by lymphocytes of the unprimed donors
(NK) may be the consequence of a certain, individually variable, degree of T cell
activation (the active cells have been shown to be within the T subset) (48, 49). Those
activated T cells that recognize the antigens determined by MHC on the target can
establish the contact and exert the killing function. IF or IF inducers recruit potential
killer cells. All evidences point to the fact that the lymphocyte cytotoxicities without
manipulation and after IF activation are similar in the ranking order of the efficiencies
exhibited by various subsets and in the sensitivities of various targets. According to
this view, the NK (and IAK) effect would be related to cytotoxic T lymphocytes when assayed on fresh targets, whereas with some cultured cell lines tested in short-term assays, as a result of yet undefined properties of their plasma membrane, events similar to the cytotoxicity in the presence of lectins could occur.

Summary

Blood lymphocytes of patients with solid tumors were assayed for cytotoxicity against autologous and allogeneic primary tumor cells. The lymphocytes killed autologous tumor cells in 7 of 25 cases (28%) and allogeneic tumor cells in 2 of 37 tests (5%). Lymphocytes from healthy donors were rarely cytotoxic for the biopsy cells, which indicates that these cells have low natural killer sensitivity.

The autoreactivity that may reflect the immunological recognition of tumor cells was not altered by pretreatment of the effectors with interferon (IF). In contrast, killing of allogeneic tumor biopsy cells was induced by IF in ~50% of tests, with the lymphocytes of both the tumor patients and the healthy donors. The mechanism of the alloreactivity is most likely a consequence of IF-induced polyclonal activation of cytotoxic potential and the lymphocytes that are committed to recognize the alloantigens expressed on the particular target manifest the killing function.

When the biopsy cells were explanted and kept in culture for 5–6 d, their susceptibility for the lymphocyte damage increased, and they were killed by the IF-treated cells also in autologous combinations. Whether this change in sensitivity is a result of qualitative or quantitative changes in antigen expression or of other changes in the properties of the cell membrane is unknown.

We thank Miss Ing-Marie Anjegård and Mrs. Maja Salsbäck for their skillful technical assistance.

Received for publication 2 January 1980.

References

1. Isaacs, A., and J. Lindenmann. 1957. Virus interference. I. The interferon. Proc. R. Soc. Biol. Med. 147:158.
2. Svet-Moldavsky, G. J., and I. Chernyakovskaya. 1967. Interferon and interaction of allogeneic normal and immune lymphocytes with L-cells. Nature (Lond.). 215:1299.
3. Lindahl, P., P. Leary, and I. Gresser. 1972. Enhancement by interferon of the specific cytotoxicity of sensitized lymphocytes. Proc. Natl. Acad. Sci. U. S. A. 69:721.
4. Trinchieri, G., D. Santoli, and H. Koprowski. 1978. Spontaneous cell-mediated cytotoxicity in humans: role of interferon and immunoglobulins. J. Immunol. 120:1849.
5. Einhorn, S., H. Blomgren, and H. Strander. 1978. Interferon and spontaneous cytotoxicity in man. I. Enhancement of the spontaneous cytotoxicity of peripheral lymphocytes by human leukocyte interferon. Int. J. Cancer. 22:405.
6. Herberman, R. B., J. R. Ortaldo, and G. D. Bonnard. 1979. Augmentation by interferon of human natural and antibody dependent cell-mediated cytotoxicity. Nature (Lond.). 277:221.
7. Gidlund, M., A. Örn, H. Wigzell, A. Senik, and I. Gresser. 1978. Enhanced NK cell activity in mice injected with interferon and interferon inducers. Nature (Lond.). 273:759.
8. Einhorn, S., H. Blomgren, and H. Strander. 1978. Interferon and spontaneous cytotoxicity in man. II. Studies in patients receiving exogenous leukocyte interferon. Acta Med. Scand. 204:477.
9. Huddlestone, J. R., T. O. Merigan, Jr., and M. B. A. Oldstone. 1979. Induction and kinetics of natural killer cells in humans following interferon therapy. Nature (Lond.). 282:417.

10. Trinchieri, G., and D. Santoli. 1978. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis. J. Exp. Med. 147:1314.

11. Gresser, I. 1977. Antitumor effects of interferon. In Cancer. A Comprehensive Treatise. F. F. Becker, editor. Plenum Publishing Corp., New York. 5:521.

12. Blomgren, H., K. Cantell, B. Johansson, C. Lagergren, U. Ringborg, and H. Strander. 1976. Interferon therapy in Hodgkin’s disease. A case report. Acta Med. Scand. 199:517.

13. Mellstedt, H., M. Björkholm, B. Johansson, A. Ahre, G. Holm, and H. Strander. 1979. Interferon therapy in myelomatosis. Lancet. II:245.

14. Merigan, T. C., K. Sikora, J. H. Breeden, R. Levy, and S. A. Rosenberg. 1978. Preliminary observations of the effect of human leukocyte interferon in non-Hodgkin’s lymphoma. N. Engl. J. Med. 299:1449.

15. Hill, N. O., E. Loeb, A. S. Pardue, G. L. Dorn, A. Khan, and J. M. Hill. 1979. Response of acute leukemia to leukocyte interferon. J. Clin. Hematol. Oncol. 9:137.

16. De Vries, J. E., M. Meyerinck, A. van Dongen, and P. Rümké. 1975. The influence of different isolation procedures and the use of target cells from melanoma cell lines and short term cultures on the non specific cytotoxic effect of lymphocytes from healthy donors. Int. J. Cancer. 15:391.

17. Becker, S., R. Kiessling, N. Lee, and G. Klein. 1978. Modulation of sensitivity to natural killer cell lysis after in vitro explantation of a mouse lymphoma. J. Natl. Cancer Inst. 61:1495.

18. Vánky, F., B. M. Vose, M. Fopp, and E. Klein. 1979. Human tumor-lymphocyte interaction in vitro. VI. Specificity of primary and secondary autologous lymphocyte mediated cytotoxicity. J. Natl. Cancer Inst. 62:1407.

19. Klein, E., F. Vánky, B. M. Vose, and M. Fopp. 1979. Tumor specific autoreactive cells in patients. In Current Trends in Tumor Immunology. S. Ferroni, S. Gorrini, R. B. Herberman, and R. A. Reisfeld editors. Garland Publishing, Inc., New York. 175.

20. Trinchieri, G., D. Santoli, R. R. Dee, and B. Knowles. 1978. Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation. J. Exp. Med. 147:1299.

21. Klein, E., M. G. Masucci, W. Berthold, and B. Blazar. Lymphocyte mediated cytotoxicity towards virus induced tumor cells. Natural and activated killer lymphocytes in man. In Viruses in Naturally Occurring Cancer. Cold Spring Harbor Laboratory, Cold Spring Harbor, N. Y. In press.

22. Vánky, F., E. Klein, J. Stjernswärd, U. Nilsson, L. Rodriguez, and Á. Péterfly. 1978. Human tumor-lymphocyte interaction in vitro. II. Conditions which improve the capacity of biopsy cells to stimulate autologous lymphocytes. Cancer Immunol. Immunother. 5:63.

23. Lozzio, C. T., and B. B. Lozzio. 1975. Human chronic myelogenous cell line with positive Philadelphia chromosome. Blood. 45:321.

24. Minowada, J., T. Ohuma, and G. E. Moore. 1972. Rosette-forming human lymphoid cell line. I. Establishment and evidence for origin of thymus derived lymphocytes. J. Natl. Cancer Inst. 49:891.

25. Vánky, F., E. Klein, J. Stjernswärd, L. Rodriguez, Á. Péterfly, L. Steiner, and U. Nilsonne. 1978. Human tumor-lymphocyte interaction in vitro. III. T-lymphocytes in autologous tumor stimulation (ATS). Int. J. Cancer. 22:6579.

26. Cantell, K., S. Hirvonen, K. E. Mogensen, and L. Pyhälä. 1974. Human leukocyte interferon: production, purification, stability and animal experiments. In The Production and Use of Interferon for the Treatment and Prevention of Human Virus Infection. C.
Waymouth, editor. American Tissue Culture Association, Rockville, Md. Monograph 3:35.

27. Strander, H., and K. Cantell. 1966. Production of interferon by human leukocytes in vitro. *Ann. Med. Exp. Biol. Fenn.* 44:285.

28. Vose, B. M., F. Vánky, and E. Klein. 1977. Lymphocyte cytotoxicity against autologous tumour biopsy cells in humans. *Int. J. Cancer* 20:512.

29. Vose, B. M., F. Vánky, M. Fopp, and E. Klein. 1978. Restricted autologous lymphocyte-toxicity in lung neoplasia. *Br. J. Cancer.* 38:375.

30. Stjernswärd, J., P. Clifford, S. Singh, and E. Svedmyr. 1968. Indications of cellular immunological reactions against autochthonous tumor in cancer patients studied in vitro. *East Afr. Med. J.* 45:484.

31. Vánky, F., and J. Stjernswärd. 1979. Lymphocyte stimulation by autologous tumor biopsy cells. In *Immunodiagnosis of Cancer.* R. B. Herberman and K. R. McIntire, editors. Marcel Dekker, Inc., New York. 998.

32. Vánky, F., B. M. Vose, M. Fopp, and E. Klein. 1979. Human tumor-lymphocyte interaction in vitro. IV. Comparison of the results with autologous tumor stimulation (ATS) and lymphocytoxicity (ALC). In *Immunodiagnosis and Immunotherapy of Malignant Tumours—Relevance to Surgery?* H. D. Flad, CH. Herfarth, and M. Betszer, editors. Springer-Verlag, Berlin. 143.

33. Cikes, M., S. Friberg, and G. Klein. 1973. Progressive loss of H-2 antigens with concomitant increase of cell surface antigen(s) determined by Moloney leukemia virus in cultured murine lymphomas. *J. Natl. Cancer Inst.* 50:347.

34. Boyse, E. A., L. J. Old, and S. Well. 1963. Antigenic properties of experimental leukemias. II. Immunological studies in vivo with C57BL/6 radiation-induced leukemias. *J. Natl. Cancer Inst.* 31:987.

35. Segerling, M., S. H. Ohanian, and T. Borsos. 1975. Chemotherapeutic drugs increase killing of tumor cells by antibody and complement. *Science (Wash. D. C.)*. 188:55.

36. Hansson, M., K. Kärre, T. Bakacs, R. Kiessling, and G. Klein. 1978. Intra- and interspecies reactivity of human and mouse natural killer (NK) cells. *J. Immunol.* 121:6.

37. Callewaert, D. M., J. Kaplan, D. F. Johnson, and W. D. Peterson, Jr. 1979. Spontaneous cytotoxicity of cultured human cell lines mediated by normal peripheral lymphocytes. II. Specificity for target antigens. *Cell. Immunol.* 42:103.

38. Saksela, E., T. Timonen, and K. Cantell. 1979. Human natural killer activity is augmented by interferon via recruitment of “pre NK” cells. *Scand. J. Immunol.* 10:257.

39. Oehler, J. R., R. L. Lindsay, M. E. Nunn, H. T. Holden, and R. B. Herberman. 1978. Natural cell-mediated cytotoxicity in rats. II. In vivo augmentation of NK-cell activity. *Int. J. Cancer.* 21:210.

40. Welsh, R. M., R. M. Zinkernagel, and L. A. Hallenbeck. 1979. Cytotoxic cells induced during lymphocytic choriomeningitis virus infection in mice. II. Specificities of the natural killer cells. *J. Immunol.* 122:475.

41. Nunn, M. E., R. B. Herberman, and H. T. Holden. 1977. Natural cell mediated cytotoxicity in mice against non lymphoid tumor cells and some normal cells. *Int. J. Cancer* 20:381.

42. Obata, Y., H. Ikeda, E. Stockert, and E. A. Boyse. 1975. Relation of Gox antigen of thymocytes to envelope glycoprotein of murine leukemia virus. *J. Exp. Med.* 141:188.

43. Waterfield, D. J., E. M. Waterfield, and G. Möller. 1974. Lymphocyte-mediated cytoxicity against tumor cells. I. Con-A activated cytotoxic effector cells exhibit immunological specificity. *Cell. Immunol.* 17:392.

44. Clark, W. R. 1975. An antigen specific component of lectin-mediated cytotoxicity. *Cell. Immunol.* 17:505.

45. Bevan, M. J., R. E. Langman, and M. Cohn. 1976. H-2 antigen specific cytopotic T cells induced by concavalin A: estimation of their relative frequency. *Eur. J. Immunol.* 6:150.

46. Stejskal, V., G. Holm, and P. Perlmann. 1973. Differential cytoxicity of activated lymphocytes on allogeneic and xenogeneic target cells. I. Activation by tuberculin and staphylococcus filtrate. *Cell. Immunol.* 8:71.
47. Galili, U., N. Galili, F. Vánky, and E. Klein. 1978. Natural species-restricted attachment of human and murine T lymphocytes to various cells. Proc. Natl. Acad. Sci. U. S. A. 75:2396.
48. Bakács, T., P. Gergely, and E. Klein. 1977. Characterization of cytotoxic human lymphocyte subpopulations: the role of Fc-receptor carrying cells. Cell. Immunol. 32:317.
49. West, W. H., G. B. Cannon, H. D. Kay, G. D. Bonnard, and R. B. Herberman. 1977. Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells. J. Immunol. 118:355.